On tonight's MAD MONEY on CNBC, BASF (NYSE: BF) in Germany is the next stock that Cramer wants to visit as an EU play, and he also thinks this company will be making some acquisitions. He does not see this as the traditional takeover stock. This one did the $80 to $120 move already, and this is over $60 Billion in market cap and he wouldn't be shocked if it goes to $150.00. He noted it is also cheaper on P/E than Dow Chemical (NYSE: DOW) and it only gets 22% of its net from North America. BASF's earnings are also becoming more and more consistent, and that can command a P/E premium from Wall Street.
Interestingly enough, Cramer also gave us a chemical stock that could be an acquisition target. We already say Lyondell Chemical (NYSE: LYO) fall to Basell, and Cramer thinks that Nova Chemicals (NYSE: NCX) is the other chemical stock that could easily be acquired. The analyst at BB&T has picked the last two buyouts in the sector and he thinks Nova Chemical could be the next target. This one has a $3.3 Billion market cap and is atthe top of its 52-week trading range. It is far under the $50.00+ highs of early 2005.
BASF is definitely a company to watch, although Cramer is probably right that it won't be acquired. We are back to a good solid manufacturing economy and emerging markets are helping all these guys out. The company has managed to be a growth engine, and if it is true that their earnings are becoming more predictable then maybe he's right. Nova is a tough one to call, particularly since I haven't looked at it closely in some time.
Jon Ogg is a partner at 24/7 Wall St.; he does not own securities in the companies he covers.
Last updated: February 09, 2012: 01:49 PM
Hot Stocks
DailyFinance Headlines
- Readers' Tips for Financial Renewal, Part 4: Get the Right Job
- Tax Time for Single Parents Can Be Doubly Aggravating
- BlackBerry Loses to Apple Again
- DVDs Are Dying, and There's Worse News Ahead for Hollywood
- The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Benzinga Headlines
- The Pepsi Challenge for 8,700 People is to Find a New Job
- How to Profit From Surging Chinese Prices
- Credit Suisse is the Latest Swiss Bank to Disappoint
- Vodafone Misses Quarterly Revenue
- CVS Profit Up as Walgreen's Customers Defect
TheFlyOnTheWall.com Headlines
- Taleo downgraded to Neutral from Buy at Citigroup
- Occidental Petroleum raises annual dividend 17% to $2.16 per share
- Perficient acquires PointBridge Solutions
- Leapfrog calls more active puts into the expected release of Q4
- Philip Morris says its E.U. sales volume could increase in 2012
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Readers' Tips for Financial Renewal, Part 4: Get the Right Job
- Tax Time for Single Parents Can Be Doubly Aggravating
- BlackBerry Loses to Apple Again
- DVDs Are Dying, and There's Worse News Ahead for Hollywood
- The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal

